First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
Abstract
Enhancing tumor-specific T-cell immunity by inhibiting programmed death ligand 1 (PD-L1)-programmed death 1 (PD-1) signaling has shown promise in the treatment of extensive-stage small-cell lung cancer. Combining checkpoint inhibition with cytotoxic chemotherapy may have a synergistic effect and improve efficacy.We conducted this double-blind, placebo-controlled, phase 3 trial to evaluate atezolizumab plus carboplatin and etoposide in patients...
Paper Details
Title
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
Published Date
Dec 6, 2018
Volume
379
Issue
23
Pages
2220 - 2229
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History